Literature DB >> 2417295

Elevation of serum pancreatic secretory trypsin inhibitor (PSTI) in patients with serious injury.

M Ogawa, K Matsuda, T Shibata, Y Matsuda, T Ukai, M Ohta, T Mori.   

Abstract

Pancreatic secretory trypsin inhibitor (PSTI) in serum was measured periodically in 15 patients with serious abdominal and non-abdominal injuries. From the second or third posttraumatic day, serum PSTI began to rise. Elevation of serum PSTI to more than twice the initial value was seen in 93% of the patients following serious injury. In uneventful cases, it declined and returned to the level at the time of admission within 14 days, but in the patients with serious inflammations and in the patient who died, it remained elevated. The change in the concentration of serum PSTI was significantly correlated with those of the acute phase reactants (fibrinogen and alpha 1-antitrypsin). There was no correlation between the level of serum PSTI and serum amylase activity or creatinine.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2417295

Source DB:  PubMed          Journal:  Res Commun Chem Pathol Pharmacol        ISSN: 0034-5164


  4 in total

1.  Reaction of a tumour-associated trypsin inhibitor with serine proteinases associated with coagulation and tumour invasion.

Authors:  U Turpeinen; E Koivunen; U H Stenman
Journal:  Biochem J       Date:  1988-09-15       Impact factor: 3.857

2.  Role of the tumor-associated trypsin inhibitor SPINK1 in cancer development.

Authors:  Ulf-Håkan Stenman
Journal:  Asian J Androl       Date:  2011-05-23       Impact factor: 3.285

3.  Increased serum levels of tumour-associated trypsin inhibitor independently predict a poor prognosis in colorectal cancer patients.

Authors:  Alexander Gaber; Björn Nodin; Kristina Hotakainen; Elise Nilsson; Ulf-Håkan Stenman; Anders Bjartell; Helgi Birgisson; Karin Jirström
Journal:  BMC Cancer       Date:  2010-09-17       Impact factor: 4.430

4.  Tumour-associated trypsin inhibitor (TATI) in human ovarian cyst fluid. Comparison with CA 125 and CEA.

Authors:  H Halila; M L Huhtala; C Haglund; S Nordling; U H Stenman
Journal:  Br J Cancer       Date:  1987-08       Impact factor: 7.640

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.